Clinical study of Repatha: it does not affect patients’ cognitive function and significantly reduce blood lipid and prevent coronary atherosclerosis

Abstract

Hyperlipidemia has always been one of the serious factors endangering human health.  It is a high-risk factor for coronary heart disease, myocardial infarction, cerebral infarction and other diseases. Blood lipid management is very important for the control of cardiovascular and cerebrovascular diseases. Repatha, as a new type of hypolipidemic drug, has shown good effects and no serious adverse reactions in clinical trials. Although at present, drugs that reduce LDL-C, especially statins, play an important role in the prevention of cardiovascular disease, however, a considerable proportion of patients still failed to reach the LDL-C target value specified in the relevant guidelines. Amgen recently released phase III clinical trial data that shows the good curative effect of repatha in combination with statins on patients with hyperlipidemia. Repatha (evolocumab), a PCSK9 inhibitor, is a necessary adjunctive treatment option for patients with inherited high cholesterol who cannot control their high LDL-C with other lipid-lowering agents alone. This review focused on hyperlipidemia and its clinical manifestations. Repatha’s basic information, clinical trial process, data and results were also included.